

(b) The licensee or certificate holder shall verify attendance at approved continuing education programs by a certificate of attendance or by a statement from the instructor of the offering. The verification shall include:

- 1. The title, including the specific designation of whether the course or program is clinical practice, ethics, cultural competency, or general social work, date, and location of course offering;
- 2. Name and license or certificate number of the attendee;
- 3. Number of credits awarded;
- 4. Name and \*[original]\* signature of officer or responsible party; and
- 5. The number of continuing education hours.

(c) The licensee or certificate holder shall verify individual activities by retaining the following:

- 1.-2. (No change.)
- 3. For teaching appointments, copies of the syllabus, bibliography, course outline, and verification from the academic institution that the course was "new." For the purpose of this paragraph, "new" represents a course that the licensee or certificate holder has not taught previously in any educational setting.

(d)-(e) (No change.)

13:44G-6.7 Board recognition of continuing education approval entities

(a) An entity that wishes to obtain Board recognition as an entity that may approve continuing education courses shall submit the approval entity applicant fee set forth at N.J.A.C. 13:44G-14.1(a)16i and apply to the Board for such recognition in writing, indicating that it:

- 1. Requires an applicant for continuing education course approval to indicate whether it has applied to another entity for approval and if such application has been denied by the other entity;
- 2. Has a complaint process for continuing education courses that have not been approved with an option to appeal to the Board if the sponsor is displeased with the results of that process;
- 3. Has a complaint process through which attendees of approved continuing education courses may register complaints with the entity with an option to appeal to the Board if an attendee is displeased with the results of the process;
- 4. Lists all approved continuing education courses on its website;
- 5. Requires courses to maintain attendance records for five years;
- 6. Utilizes only certified social workers, licensed social workers or licensed clinical social workers in good standing to review continuing education courses;
- 7. Approves continuing education courses only, not continuing education sponsors;
- 8. Requires that approved continuing education courses comply with the requirements of N.J.A.C. 13:44G-6.3;
- 9. Sets forth, in documentation sent to an approved course, the number of credits contained in the course and whether these credits are in clinical practice, ethics, cultural competency, or general social work. The entity shall require that approved courses provide this information to course attendees;
- 10. Maintains records as to continuing education course approvals and denials; and
- 11. Responds to applications for continuing education course approval within 90 days of receipt of a request.

(b) Board recognition shall be valid for one year. An entity shall reapply for Board recognition by submitting the information required under (a) above.

(c) The Board may revoke recognition of an entity's ability to approve continuing education courses if the Board becomes aware that the entity is not complying with the requirements of (a) above.

(d) An entity that is recognized to approve continuing education courses shall not approve any continuing education course that it provides.

SUBCHAPTER 8. CLINICAL SUPERVISION

13:44G-8.1 Clinical supervision

(a) All LSWs shall not engage in independent private clinical social work practice and all LSWs engaged in clinical social work practice shall have clinical supervision in accordance with the following standards:

1. Clinical supervision shall consist of contact between a social worker and a supervisor during which at least the following occurs:

- i.-iv. (No change.)
- v. The supervisor provides at least one hour of face-to-face individual or group clinical supervision per week;
- 2. Until July 7, 2004, clinical supervision may be rendered by:
  - i.-iii. (No change.)
  - iv. Any other supervisor the Board may deem acceptable;
  - 3. All applicants shall obtain the Board's prior written approval of any person rendering supervision other than a person identified in (a)2i through iii above;

4. Any LSW who has entered into a supervisory relationship with a supervisor pursuant to (a)2 above may continue the supervisory relationship;

- 5. Clinical supervision shall be rendered by an LCSW who:
  - i. Has been licensed as an LCSW for a minimum of three years; and
  - ii. Has completed at least 20 continuing education credits of post-graduate course-work related to clinical supervision offered by either **\*the National Association of Social Workers (NASW) or\*** a sponsor approved by ASWB \*[or the National Association of Social Workers (NASW)]\*, or an educational program approved by the Council on Social Work Education (CSWE).

6. The supervisor shall retain responsibility for the standards of clinical social work practice with respect to treatment being rendered to the client;

7. The supervisor shall refer the clients to the social worker unless the social worker is employed by an agency and obtains supervision pursuant to (d) below;

8. The supervisor or the supervisor's employer shall receive the fee paid by clients for services performed by the social worker engaged in a supervisory relationship; and

- 9. (No change in text.)
- (b)-(f) (No change.)

SUBCHAPTER 14. FEES

13:44G-14.1 Fees

- (a) Charges for licensure, certification, and other services:
  - 1.-15. (No change.)
  - 16. Continuing education fees:
    - i. Continuing education sponsors approval entity. . . . . \$100.00

(a)

**DIVISION OF CONSUMER AFFAIRS**  
**CONTROLLED DANGEROUS SUBSTANCES**  
**Schedules of Controlled Dangerous Substances**  
**Adopted Amendment: N.J.A.C. 13:45H-10.1**

Proposed: August 6, 2012 at 44 N.J.R. 2038(a).  
 Adopted: October 23, 2012 by Eric T. Kanefsky, Acting Director,  
 Division of Consumer Affairs.  
 Filed: October 24, 2012 as R.2012 d.192, **without change**.  
 Authority: N.J.S.A. 24:21-3.a. and 24:21-5.a.  
 Effective Date: November 19, 2012.  
 Expiration Date: February 15, 2015.

**Summary of Public Comments and Agency Responses:**

The Division received two comments on the proposal from the following:

- 1. Debra L. Wentz, Ph.D., Chief Executive Officer, New Jersey Association of Mental Health and Addiction Agencies, Inc.; and
- 2. Lawrence Downs, JD, CEO & General Counsel, Medical Society of New Jersey.

COMMENT: Ms. Wentz, on behalf of the New Jersey Association of Mental Health and Addiction Agencies, Inc. (NJAMHAA) expressed support for the proposed amendment, which will place synthetic cannabinoids in Schedule I under the New Jersey Controlled Dangerous

Substances Act. Ms. Wentz noted that NJAMHAA hopes that the proposed amendment will reduce access to this drug class. The commenter also expressed support for the scheduling of general structural classes of cannabinoids set forth in the proposed amendment.

RESPONSE: The Division appreciates the commenter's support.

COMMENT: Mr. Downs, on behalf of the Medical Society of New Jersey, expressed support for the Division's proposed permanent addition of synthetic cannabinoids to Schedule I substances under the State CDS schedules. The commenter noted that the Medical Society of New Jersey previously provided a medical toxicologist to testify on the deleterious effects of synthetic cannabinoids and the serious risk they pose to public health and safety, during the New Jersey Attorney General's press conference announcing the Statewide ban on all types of synthetic cannabinoids.

RESPONSE: The Division appreciates the commenter's support.

#### Federal Standards Statement

A Federal standards analysis is not required because the adopted amendment is governed by the New Jersey Controlled Dangerous Substances Act, N.J.S.A. 24:21-1 et seq., specifically N.J.S.A. 24:21-3.a. and 24:21-5.a. Although New Jersey has adopted, in N.J.A.C. 13:45H-10.1(a), the Federal controlled dangerous substances Schedules I through V codified at 21 CFR 1308.11 through 1308.15, as amended and supplemented, the Director is authorized under N.J.S.A. 24:21-3 to add, delete, or reschedule substances under the New Jersey Controlled Dangerous Substances Act.

Full text of the adoption follows:

13:45H-10.1 Schedules of controlled dangerous substances

(a)-(d) (No change.)

(e) In accordance with (d) above, the following substances shall be designated and controlled as Schedule I controlled dangerous substances:

1.-8. (No change.)

9. Synthetic cannabinoids. Synthetic cannabinoids include any material, compound, mixture, or preparation that is not listed as a controlled dangerous substance in Schedules I through V, is not a Federal Food and Drug Administration (FDA) approved drug, and contains any quantity of the following substances, their salts, isomers (whether optical, positional, or geometric), homologues (analogs), and salts of isomers and homologues (analogs), unless specifically excepted, whenever the existence of these salts, isomers, homologues (analogs), and salts of isomers and homologues (analogs) is possible within the specific chemical designation:

i. Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to: JWH 015, JWH 018, JWH 019, JWH 073, JWH 081, JWH 122, JWH 200, JWH 210, JWH 398, AM 2201, and WIN 55 212;

ii. Naphthylmethylindoles. Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to: JWH-175 and JWH-184;

iii. Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to: JWH 307;

iv. Naphthylmethylindenes. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the

indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to: JWH-176;

v. Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited to: RCS-8 (SR-18), JWH 250, JWH 203, JWH-251, and JWH-302;

vi. Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent. Examples of this structural class include, but are not limited to: CP 47,497 (and homologues (analogs)), cannabicyclohexanol, and CP 55,940;

vii. Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples of this structural class include, but are not limited to: AM 694, Pravadolone (WIN 48,098), RCS 4, and AM-679;

viii. [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone. Examples of this structural class include, but are not limited to: WIN 55,212-2;

ix. (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl) - 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 7370. Examples of this structural class include, but are not limited to: HU-210;

x. Adamantoylindoles. Any compound containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the adamantyl ring system to any extent. Examples of this structural class include, but are not limited to: AM-1248; or

xi. Any other synthetic chemical compound that is a cannabinoid receptor agonist and mimics the pharmacological effect of naturally occurring cannabinoids that is not listed in Schedules II through V or is not an FDA-approved drug.

(a)

## DIVISION OF GAMING ENFORCEMENT

### Gaming Equipment Rules of the Games Deuce of the Dragon

Temporary Adoption of Amendment: N.J.A.C.  
13:69E-1.19

Temporary Adoption of New Rules: N.J.A.C. 13:69E-  
1.13AA and 13:69F-41

Authority: N.J.S.A. 5:12-5, 63.c, 69.e, 70.f, 99.a, and 100.

Take notice that the Division of Gaming Enforcement shall, pursuant to N.J.S.A. 5:12-69.e, conduct an experiment for the purpose of determining whether the authorized game of "Deuce of the Dragon" is suitable for casino use.

The experiment will be conducted in accordance with temporary rules, which shall be available in each casino participating in the experiment, and shall also be available from the Division upon request.